You are here: Industry Insights > fostamatinib

News List

Rigel Pharmaceuticals Provides Update on COVID-19 Program prnewswire
August 16, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that clinical data submitted in late-May from a 59-patient NIH/NHLBI-sponsored Phase 2 trial of fostamatinib.
Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China prnasia
August 05, 2021
Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced today that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong, S.A.R., China and Macau, S.A
Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial prnewswire
June 30, 2021
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial in hospitalized patients with COVID-19.
Rigel concludes subject enrolment in NIH-sponsored Covid-19 trial pharmaceutical-technology
March 15, 2021
Rigel Pharmaceuticals has concluded patient enrolment in a Phase II clinical trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, for treating hospitalised Covid-19 patients.
Serum Institute of India plans clinical trials of second Covid-19 vaccine pharmaceutical-technology
February 02, 2021
Serum Institute of India (SII) has announced plans to conduct clinical trials of another Covid-19 vaccine in the country, with hopes to launch it in June.
Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients prnewswire
February 01, 2021
Rigel Pharmaceuticals, Inc. announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel's ongoing Phase 3 ...
Rigel Finalizes Study Design of Fostamatinib Trial for Warm Autoimmune Hemolytic Anemia americanpharmaceuticalreview
December 01, 2020
Rigel Pharmaceuticals has reached agreement with the U.S. Food and Drug Administration (FDA) on the final design of its FORWARD study, a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm autoimmune hemolytic ...
Rigel, Inova Enrolls First Patients in Fostamatinib Trial for Hospitalized COVID-19 Patients americanpharmaceuticalreview
October 16, 2020
Rigel Pharmaceuticals announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.
Rigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 27, 2020
Rigel Pharmaceuticals announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients.
Rigel Announces Trial of Fostamatinib for COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Rigel Pharmaceuticals announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of COVID-19 ...

Previous page 1 2 Next page